We advised Immatics on the offering

Davis Polk advised Immatics N.V. in connection with its $125 million SEC-registered direct offering of ordinary shares. The ordinary shares are listed on Nasdaq under the symbol “IMTX.”

Immatics, a clinical-stage biopharmaceutical company, is the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers, and is committed to making a meaningful impact on the lives of patients with cancer. Immatics’ cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.

The Davis Polk capital markets team included partner Yasin Keshvargar, counsel David (Wei Fu) Li and associate Xuanling Xu. Partner Ethan R. Goldman, counsel Christopher A. Baratta and associate Fred (Chen) Fu provided tax advice. Partner David R. Bauer and associate Hannah Coleman provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post